Arbutus Biopharma (ABUS) Equity Average (2011 - 2026)

Arbutus Biopharma has disclosed Equity Average across 15 years of filings, most recently posting $168.4 million for Q1 2026.

• Equity Average for Q1 2026 came in at $168.4 million, up 90.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $168.4 million (up 90.77% YoY), and the FY2025 annual result was $87.0 million, down 14.48% from the prior year.
• Equity Average came in at $168.4 million for Q1 2026 at Arbutus Biopharma, up from $77.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $168.4 million in Q1 2026 to a low of $77.0 million in Q4 2025.
• The 5-year median for Equity Average is $118.5 million (2024), against an average of $122.2 million.
• Across the five-year window, Equity Average tumbled 31.62% in 2025 and surged 90.77% in 2026, its largest moves.
• Arbutus Biopharma's Equity Average stood at $141.2 million in 2022, then dropped by 20.19% to $112.7 million in 2023, then fell by 9.36% to $102.1 million in 2024, then dropped by 24.62% to $77.0 million in 2025, then jumped by 118.71% to $168.4 million in 2026.
• The last three Equity Average figures came in at $168.4 million (Q1 2026), $77.0 million (Q4 2025), and $80.2 million (Q3 2025), per Business Quant data.